12:00 AM
Jan 30, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

AMR-001: Phase II started

NeoStem's Amorcyte LLC company began the double-blind, placebo-controlled, U.S. Phase II PreSERVE trial to evaluate AMR-001 given 5-11 days...

Read the full 73 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >